COMBSecretomics: A Pragmatic Methodological Framework for Higher-order Drug Combination Analysis Using Secretomics

Overview

Journal PLoS One

Specialties General Medicine
Science

Date 2020 May 15

PMID 32407402

Authors

Efthymia Chantzi

Michael Neidlin

George A Macheras

Leonidas G Alexopoulos

Mats G Gustafsson

Affiliations

Soon will be listed here.

Abstract

Multi drug treatments are increasingly used in the clinic to combat complex and co-occurring diseases. However, most drug combination discovery efforts today are mainly focused on anticancer therapy and rarely examine the potential of using more than two drugs simultaneously. Moreover, there is currently no reported methodology for performing second- and higher-order drug combination analysis of secretomic patterns, meaning protein concentration profiles released by the cells. Here, we introduce COMBSecretomics (https://github.com/EffieChantzi/COMBSecretomics.git), the first pragmatic methodological framework designed to search exhaustively for second- and higher-order mixtures of candidate treatments that can modify, or even reverse malfunctioning secretomic patterns of human cells. This framework comes with two novel model-free combination analysis methods; a tailor-made generalization of the highest single agent principle and a data mining approach based on top-down hierarchical clustering. Quality control procedures to eliminate outliers and non-parametric statistics to quantify uncertainty in the results obtained are also included. COMBSecretomics is based on a standardized reproducible format and could be employed with any experimental platform that provides the required protein release data. Its practical use and functionality are demonstrated by means of a proof-of-principle pharmacological study related to cartilage degradation. COMBSecretomics is the first methodological framework reported to enable secretome-related second- and higher-order drug combination analysis. It could be used in drug discovery and development projects, clinical practice, as well as basic biological understanding of the largely unexplored changes in cell-cell communication that occurs due to disease and/or associated pharmacological treatment conditions.

References

Caruso Bavisotto C, Scalia F, Marino Gammazza A, Carlisi D, Bucchieri F, de Macario E . Extracellular Vesicle-Mediated Cell⁻Cell Communication in the Nervous System: Focus on Neurological Diseases. Int J Mol Sci. 2019; 20(2). PMC: 6359416. DOI: 10.3390/ijms20020434. View

Pemovska T, Bigenzahn J, Superti-Furga G . Recent advances in combinatorial drug screening and synergy scoring. Curr Opin Pharmacol. 2018; 42:102-110. PMC: 6219891. DOI: 10.1016/j.coph.2018.07.008. View

Palmer A, Sorger P . Combination Cancer Therapy Can Confer Benefit via Patient-to-Patient Variability without Drug Additivity or Synergy. Cell. 2017; 171(7):1678-1691.e13. PMC: 5741091. DOI: 10.1016/j.cell.2017.11.009. View

Wetmore B, Clewell R, Cholewa B, Parks B, Pendse S, Black M . Assessing bioactivity-exposure profiles of fruit and vegetable extracts in the BioMAP profiling system. Toxicol In Vitro. 2018; 54:41-57. PMC: 6635950. DOI: 10.1016/j.tiv.2018.09.006. View

Regan-Fendt K, Xu J, DiVincenzo M, Duggan M, Shakya R, Na R . Synergy from gene expression and network mining (SynGeNet) method predicts synergistic drug combinations for diverse melanoma genomic subtypes. NPJ Syst Biol Appl. 2019; 5:6. PMC: 6391384. DOI: 10.1038/s41540-019-0085-4. View

Berg E, Kunkel E, Hytopoulos E, Plavec I . Characterization of compound mechanisms and secondary activities by BioMAP analysis. J Pharmacol Toxicol Methods. 2005; 53(1):67-74. DOI: 10.1016/j.vascn.2005.06.003. View

Caccia D, Dugo M, Callari M, Bongarzone I . Bioinformatics tools for secretome analysis. Biochim Biophys Acta. 2013; 1834(11):2442-53. DOI: 10.1016/j.bbapap.2013.01.039. View

Tekin E, White C, Kang T, Singh N, Cruz-Loya M, Damoiseaux R . Prevalence and patterns of higher-order drug interactions in . NPJ Syst Biol Appl. 2018; 4:31. PMC: 6119685. DOI: 10.1038/s41540-018-0069-9. View

Zullo J, Matsumoto K, Xavier S, Ratliff B, Goligorsky M . The cell secretome, a mediator of cell-to-cell communication. Prostaglandins Other Lipid Mediat. 2015; 120:17-20. PMC: 4575600. DOI: 10.1016/j.prostaglandins.2015.03.012. View

10.

Brown K, Seol H, Pillai D, Sankoorikal B, Formolo C, Mac J . The human secretome atlas initiative: implications in health and disease conditions. Biochim Biophys Acta. 2013; 1834(11):2454-61. PMC: 3755092. DOI: 10.1016/j.bbapap.2013.04.007. View

11.

Poubelle P, Page N, Longchamps M, Sampaio Moura N, Beck D, Aksentijevich I . The use of leukocytes' secretome to individually target biological therapy in autoimmune arthritis: a case report. Clin Transl Med. 2019; 8(1):19. PMC: 6548783. DOI: 10.1186/s40169-019-0236-7. View

12.

Brown K, Formolo C, Seol H, Marathi R, Duguez S, An E . Advances in the proteomic investigation of the cell secretome. Expert Rev Proteomics. 2012; 9(3):337-45. PMC: 3500636. DOI: 10.1586/epr.12.21. View

13.

Tan X, Hu L, Luquette 3rd L, Gao G, Liu Y, Qu H . Systematic identification of synergistic drug pairs targeting HIV. Nat Biotechnol. 2012; 30(11):1125-30. PMC: 3494743. DOI: 10.1038/nbt.2391. View

14.

Geary N . Understanding synergy. Am J Physiol Endocrinol Metab. 2012; 304(3):E237-53. DOI: 10.1152/ajpendo.00308.2012. View

15.

Beppler C, Tekin E, Mao Z, White C, McDiarmid C, Vargas E . Uncovering emergent interactions in three-way combinations of stressors. J R Soc Interface. 2016; 13(125). PMC: 5221529. DOI: 10.1098/rsif.2016.0800. View

16.

Tekin E, Beppler C, White C, Mao Z, Savage V, Yeh P . Enhanced identification of synergistic and antagonistic emergent interactions among three or more drugs. J R Soc Interface. 2016; 13(119). PMC: 4938094. DOI: 10.1098/rsif.2016.0332. View

17.

Vivek-Ananth R, Mohanraj K, Vandanashree M, Jhingran A, Craig J, Samal A . Comparative systems analysis of the secretome of the opportunistic pathogen Aspergillus fumigatus and other Aspergillus species. Sci Rep. 2018; 8(1):6617. PMC: 5919931. DOI: 10.1038/s41598-018-25016-4. View

18.

Vlot A, Aniceto N, Menden M, Ulrich-Merzenich G, Bender A . Applying synergy metrics to combination screening data: agreements, disagreements and pitfalls. Drug Discov Today. 2019; 24(12):2286-2298. DOI: 10.1016/j.drudis.2019.09.002. View

19.

Chantzi E, Jarvius M, Niklasson M, Segerman A, Gustafsson M . COMBImage2: a parallel computational framework for higher-order drug combination analysis that includes automated plate design, matched filter based object counting and temporal data mining. BMC Bioinformatics. 2019; 20(1):304. PMC: 6549340. DOI: 10.1186/s12859-019-2908-0. View

20.

Cheng F, Kovacs I, Barabasi A . Network-based prediction of drug combinations. Nat Commun. 2019; 10(1):1197. PMC: 6416394. DOI: 10.1038/s41467-019-09186-x. View